Welcome to Francis Academic Press

Frontiers in Medical Science Research, 2023, 5(6); doi: 10.25236/FMSR.2023.050606.

Clinical application value of bioabsorbable stent in percutaneous coronary intervention for non-left main lesion

Author(s)

Zhang Yirong1, Guan Mengyun2, Shen Changyin2, Mei Li1

Corresponding Author:
Zhang Yirong
Affiliation(s)

1Liupanshui People's Hospital, Liupanshui, Guizhou, 553000, China

2Zunyi Medical University, Zunyi, Guizhou, 563000, China

Abstract

Non-left main coronary artery disease is a common coronary artery disease, and about 1/5 patients need percutaneous coronary intervention (PCI). This article reviews the advantages, safety and limitations of using bioabsorbable stents in clinical treatment of non-left main coronary artery disease.

Keywords

bioabsorbable scaffold (BRS)

Cite This Paper

Zhang Yirong, Guan Mengyun, Shen Changyin, Mei Li. Clinical application value of bioabsorbable stent in percutaneous coronary intervention for non-left main lesion. Frontiers in Medical Science Research (2023) Vol. 5, Issue 6: 34-37. https://doi.org/10.25236/FMSR.2023.050606.

References

[1] Cui Zhanqian, Zhao Guowei, Guo Xinjun (2022). Changes of high-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 levels in patients with coronary heart disease implanted with bioabsorbable stents [J]. China Medicine, vol. 17, no. 10, pp. 1455-1458. 

[2] Fu Junhui, Huang Jing, Xu Rui, et al(2022). Preparation and biocompatibility of absorbable antibacterial biliary stent [J]. Journal of Ningbo University (Science and Technology Edition), vol. 35, no. 06, pp. 54-62. 

[3] Zhu Yongxiang, Cai Jinzan, Zhu Hao, et al(2018). Possible factors and management of early stent thrombosis after bioabsorbable stent implantation [J]. China Journal of Circulation, vol. 33, no. 03, pp. 296-298. 

[4] Gao Xun, Ding Song, He Ben, et al(2017). Application status of bioabsorbable stent in percutaneous coronary intervention [J]. China Journal of Interventional Cardiology, vol. 25, no. 03, pp. 163-165. 

[5] Wang Yeping, Wang Yueqin, Liu Wenbin, et al(2022). Comparative study of bioabsorbable stent and drug-eluting stent in the treatment of coronary arteriopathy [J]. Journal of Southeast University (Medical Edition), vol. 41, no. 01, pp. 26-34. 

[6] Wu Yizhe, Yin Jiasheng, Ge Lei, et al(2020). Clinical results of a 4-year randomized controlled study on the treatment of in situ coronary artery stenosis with XINSORB bioabsorbable sirolimus eluting stent [J]. China Journal of Interventional Cardiology, vol. 28, no. 09, pp. 493-499. 

[7] Liang Yubo, Lin Xin, Che Qianqiu, Sun Ruimin, et al(2019). Systematic evaluation of the safety and effectiveness of bioabsorbable stents in percutaneous coronary intervention [J]. China Journal of Evidence-based Cardiovascular Medicine, vol. 11, no. 02, pp. 148-154. 

[8] Li Chongjian, Xu Bo, Song Lei, et al (2021). Safety and feasibility of the first use of the bioabsorbable scaffold Firesorb in human body for the treatment of coronary heart disease: results of four-year clinical follow-up [J]. Chinese journal of cardiology, vol. 49, no. 02, pp. 128-135. 

[9] Ke Junsong, Yang Wenxue, Zhang Hongyu, et al(2021). Meta-analysis of the safety and effectiveness of bioabsorbable stents and drug-eluting stents in the treatment of acute myocardial infarction [J]. China Journal of Interventional Cardiology, vol. 29, no. 01, pp. 35-43. 

[10] Han Zongmao, Gao Jie, Gao Chuanyu, et al(2021). The long-term prognosis of patients with coronary heart disease after percutaneous coronary intervention [J]. Chinese Journal of Practical Diagnosis and Treatment, vol. 35, no. 01, pp. 19-22.